FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
Positive Phase III Results of Genentech’s Investigational Medicine OCREVUS™ (Ocrelizumab) Published in New England Journal of Medicine
These funds offer thoughtful investments in healthcare, not tactical plays.
Maxygen MAXY announced that its partner Roche RHHBY placed a hold on development of Maxy-Alpha--the first of Maxygen's shuffled proteins to enter clinical development--and we're lowering our fair value estimate accordingly. While we had only placed a 20% probability on the eventual approval of ...
This ETF holds a swath of large- and mid-cap U.S. healthcare companies.
Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.
First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.
Ariel International marks the firm’s first foray into foreign-stock investing. It has been a performance success so far.
Readers say diversification and exposure to good companies call for looking beyond the U.S.